Abstract
p53–p21 pathway mediates cardiomyocyte hypertrophy and apoptosis and is upregulated in diabetic cardiomyopathy (DbCM). We investigated role of microRNAs in regulating p53–p21 pathway in high glucose (HG)-induced cardiomyocyte hypertrophy and apoptosis. miR-30c and miR-181a were identified to target p53. Cardiac expression of microRNAs was measured in diabetic patients, diabetic rats, and in HG-treated cardiomyocytes. Effect of microRNAs over-expression and inhibition on HG-induced cardiomyocyte hypertrophy and apoptosis was examined. Myocardial expression of p53 and p21 genes was increased and expression of miR-30c and miR-181a was significantly decreased in diabetic patients, DbCM rats, and in HG-treated cardiomyocytes. Luciferase assay confirmed p53 as target of miR-30c and miR-181a. Over-expression of miR-30c or miR-181a decreased expression of p53, p21, ANP, cardiomyocyte cell size, and apoptosis in HG-treated cardiomyocytes. Concurrent over-expression of these microRNAs resulted in greater decrease in cardiomyocyte hypertrophy and apoptosis, suggesting a synergistic effect of these microRNAs. Our results suggest that dysregulation of miR-30c and miR-181a may be involved in upregulation of p53–p21 pathway in DbCM.
Similar content being viewed by others
References
Avogaro A, Vigili de Kreutzenberg S, Negut C, Tiengo A, Scognamiglio R (2004) Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 93:13A–16A
Anguita Sánchez M (2002) Prevention and treatment of congestive heart failure in diabetic patients. Rev Esp Cardiol 55:1083–1087
Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, Pereira FC, Reis F (2013) Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol 12:44
Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Kajstura J (2001) Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50:2363–2375
Letonja M, Petrovič D (2014) Is diabetic cardiomyopathy a specific entity? World J Cardiol 6:8–13
Abid S, Houssaïni A, Mouraret N, Marcos E, Amsellem V, Wan F, Dubois-Randé JL, Derumeaux G, Boczkowski J, Motterlini R, Adnot S (2014) p21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension. Arterioscler Thromb Vasc Biol 34:304–312
Chatterjee A, Mir SA, Dutta D, Mitra A, Pathak K, Sarkar S (2011) Analysis of p53 and NF-κB signaling in modulating the cardiomyocyte fate during hypertrophy. J Cell Physiol 226:2543–2554
Das B, Young D, Vasanji A, Gupta S, Sarkar S, Sen S (2010) Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc Res 87:524–534
Hernández JS, Barreto-Torres G, Kuznetsov AV, Khuchua Z, Javadov S (2014) Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. J Cell Mol Med 18:709–720
Ikeda S, Hamada M, Hiwada K (1999) Cardiomyocyte apoptosis with enhanced expression of P53 and Bax in right ventricle after pulmonary arterial banding. Life Sci 65:925–933
Jiang FL, Leo S, Wang XG, Li H, Gong LY, Kuang Y, Xu XF (2013) Effect of tanshinone IIA on cardiomyocyte hypertrophy and apoptosis in spontaneously hypertensive rats. Exp Ther Med 6:1517–1521
Kimura TE, Jin J, Zi M, Prehar S, Liu W, Oceandy D, Abe J, Neyses L, Weston AH, Cartwright EJ, Wang X (2010) Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 106:961–970
Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I (2007) p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444–448
Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H, Liao Y, Okazaki H, Asai M, Hirata A, Fujita M, Asano Y, Yamazaki S, Asanuma H, Hori M, Kitakaze M (2006) Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 340:1125–1133
Vahtola E, Storvik M, Louhelainen M, Merasto S, Lakkisto P, Lakkisto J, Tikkanen I, Kaheinen P, Levijoki J, Mervaala E (2011) Diabetic cardiomyopathy and post-infarct ventricular remodelling: effects of levosimendan in a rodent model of type II diabetes. Basic Clin Pharmacol Toxicol 109:387–397
Vahtola E, Louhelainen M, Merasto S, Martonen E, Penttinen S, Aahos I, Kytö V, Virtanen I, Mervaala E (2008) Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat. J Hypertens 26:334–344
Mönkemann H, De Vriese AS, Blom HJ, Kluijtmans LA, Heil SG, Schild HH, Golubnitschaja O (2002) Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids 23:331–336
Golubnitschaja O, Moenkemann H, Trog DB, Blom HJ, De Vriese AS (2006) Activation zf genes inducing cell-cycle arrest and of increased DNA repair in the hearts of rats with early streptozotocin-induced diabetes mellitus. Med Sci Monit 12:BR68–BR74
Kuwabara Y, Horie T, Baba O, Watanabe S, Nishiga M, Usami S, Izuhara M, Nakao T, Nishino T, Otsu K, Kita T, Kimura T, Ono K (2015) MicroRNA-451 Exacerbates Lipotoxicity in Cardiac Myocytes and High-Fat Diet-Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK Pathway. Circ Res 116:279–288
Zheng D, Ma J, Yu Y, Li M, Ni R, Wang G, Chen R, Li J, Fan GC, Lacefield JC, Peng T (2015) Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Diabetologia 58:1949–1958
Li X, Du N, Zhang Q, Li J, Chen X, Liu X, Hu Y, Qin W, Shen N, Xu C, Fang Z, Wei Y, Wang R, Du Z, Zhang Y, Lu Y (2014) MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis 5:e1479
Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P (2010) miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet 6:e1000795
Forini F, Kusmic C, Nicolini G, Mariani L, Zucchi R, Matteucci M, Iervasi G, Pitto L (2014) Triiodothyronine prevents cardiac ischemia/reperfusion mitochondrial impairment and cell loss by regulating miR30a/p53 axis. Endocrinology 155:4581–4590
Cheah YK, Cheng RW, Yeap SK, Khoo CH, See HS (2014) Analysis of TP53 gene expression and p53 level of human hypopharyngeal FaDu (HTB-43) head and neck cancer cell line after microRNA-181a inhibition. Genet Mol Res 13:1679–1683
Zhang M, Lv XY, Li J, Xu ZG, Chen L (2009) The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008:704045
Raut SK, Kumar A, Singh GB, Nahar U, Sharma V, Mittal A, Khullar M (2015) miR-30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy. Cardiovasc Ther 33:89–97
Chen J, Kastan MB (2010) 5′–3′-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev 24:2146–2156
Chen X, Prywes R (1999) Serum-induced expression of the cdc25AGene by relief of E2F-mediated repression. Mol Cell Biol 19:4695–4702
Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Engelhardt S (2013) MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127:2097–2106
Wang JX, Zhang XJ, Feng C, Sun T, Wang K, Wang Y, Li PF (2015) MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity. Cell Death Dis 6:e1677
Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L, Jacob J, Frampton AE, Krell J, Coombes R, Harding SE, Lyon AR, Stebbing J (2015) Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis. Cell Death Dis 6:e1754
Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE (2009) miR-133 and miR-30 regulate connective tissue growth factor Implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170–178
Liu Q, Du GQ, Zhu ZT, Zhang C, Sun XW, Liu JJ, Li X, Wang YS, Du WJ (2015) Identification of apoptosis-related microRNAs and their target genes in myocardial infarction post-transplantation with skeletal myoblasts. J Transl Med 13:270
Hirt MN, Werner T, Indenbirken D, Alawi M, Demin P, Kunze AC, Stenzig J, Starbatty J, Hansen A, Fiedler J, Thum T, Eschenhagen T (2015) Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J Mol Cell Cardiol 81:1–9
Balderman JA, Lee HY, Mahoney CE, Handy DE, White K, Annis S, Lebeche D, Hajjar RJ, Loscalzo J, Leopold JA (2012) Bone morphogenetic protein-2 decreases MicroRNA-30b and MicroRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc 1:e003905
Abonnenc M, Nabeebaccus AA, Mayr U, Barallobre-Barreiro J, Dong X, Cuello F, Sur S, Drozdov I, Langley SR, Lu R, Stathopoulou K, Didangelos A, Yin X, Zimmermann WH, Shah AM, Zampetaki A, Mayr M (2013) Extracellular matrix secretion by cardiac fibroblasts role of MicroRNA-29b and MicroRNA-30c. Circ Res 113:1138–1147
Carolina G, Claudia K, Elena C, Francesco M, Milena R, Laura M, Letizia P (2013) miR-29a and miR-30c negatively regulate DNMT 3a in cardiac ischemic tissues: implications for cardiac remodelling. MicroRNA Diagn Ther 1:2084–6843
Feng HJ, Ouyang W, Liu JH, Sun YG, Hu R, Huang LH, Xian JL, Jing CF, Zhou MJ (2014) Global microRNA profiles and signaling pathways in the development of cardiac hypertrophy. Braz J Med Biol Res 7:361–368
Isserlin R, Merico D, Wang D, Vuckovic D, Bousette N, Gramolini AO, Bader GD, Emili A (2014) Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy. Mol BioSyst 11:239–251
Reddy S, Zhao M, Hu DQ, Fajardo G, Hu S, Ghosh Z, Rajagopalan V, Wu JC, Bernstein D (2012) Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 44:562–575
Wijnen WJ, van der Made I, van den Oever S, Hiller M, de Boer BA, Picavet DI, Chatzispyrou IA, Houtkooper RH, Tijsen AJ, Hagoort J, van Veen H, Everts V, Ruijter JM, Pinto YM, Creemers EE (2014) Cardiomyocyte-Specific miRNA-30c Over-Expression Causes Dilated Cardiomyopathy. PLOS ONE 9:e96290
Kuster DW, Mulders J, Ten Cate FJ, Michels M, Dos Remedios CG, da Costa Martins PA, van der Velden J, Oudejans CB (2013) MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. J Mol Cell Cardiol 65:59–66
Zhu W, Zhao Y, Xu Y, Sun Y, Wang Z, Yuan W, Du Z (2013) Dissection of Protein Interactomics Highlights MicroRNA Synergy. PLoS ONE 8:e63342
Acknowledgments
This research was supported by the Department of Science and Technology (SR/SO/HS-0049/2010). Satish K Raut is a PhD student in Department of Experimental Medicine and Biotechnology, PGIMER and was supported by Indian Council of Medical Education and Research (3/1/2(13)/CVD/2010/NCD-II), New Delhi, India.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare they have no conflict interests.
Rights and permissions
About this article
Cite this article
Raut, S.K., Singh, G.B., Rastogi, B. et al. miR-30c and miR-181a synergistically modulate p53–p21 pathway in diabetes induced cardiac hypertrophy. Mol Cell Biochem 417, 191–203 (2016). https://doi.org/10.1007/s11010-016-2729-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-016-2729-7